Protective effect of A(H5N8) stockpiled vaccine against a virus genetically identical to a human isolate of bovine A(H5N1) influenza virus
This finding highlights the vaccine's potential utility during the early phase of an emerging pandemic threat.
Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants
maternal RSVpreF vaccination was associated with 78% to 81% reduction in RSV-associated hospitalization from birth through 6 months of age, with the highest vaccine effectiveness in earliest age intervals.
The receptor landscape of influenza A viruses
Authors discuss the structural determinants of sialic acid and MHC-II receptor engagement, the plasticity of HA receptor-binding sites, and the consequences of exclusive or dual receptor usage on host range and zoonotic potential.
Occupationally Exposed and General Population Antibody Profiles to Influenza A Viruses Circulating in Swine as Indication of Zoonotic Risk
Population immunity gaps heighten zoonotic risk to circulating swine H1 and H3 strains.
Mass mortality events in aquatic mammals caused by avian influenza viruses
The available serological data suggest that enzootic circulation of Avian Influenza in aquatic mammals is limited.
Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice
Novel H5-MNP vaccine technology could potentially induce protective immunity against pandemic influenza viruses in individuals with pre-existing seasonal influenza HA immunity.
First Ecuadorian Pediatric Case of Multisystem and Neurological Involvement Associated with Influenza A—H5N1 Virus—Case Report
This report describes the first confirmed Ecuadorian pediatric case of H5N1-associated encephalitis and multisystem organ failure in a previously healthy 9-year-old female following direct contact with infected poultry.
Genomic Surveillance Uncovers the Silent Spread of Avian Influenza Virus (H5N1 2.3.4.4b) Among Wild Birds and Mammals Along Brazil’s Southern Coast
Reinforces the importance of continuous genomic surveillance, especially in AIV hosts that do not show signs of infection, to enhance the One-Health assessment approach.
